Mochi Health tirzepatide: November 2026 price and position
As of November 20, 2026, Mochi Health charges $169 a month for compounded tirzepatide month to month, all-in, according to its own page. That is a starting-dose figure; the price rises with the dose, so ask for the maintenance-dose price in writing.
Released · Last reviewed · how we verify
Mochi Health tirzepatide prices, read November 20, 2026
| Measure | Amount | Basis |
|---|---|---|
| Month to month, all-in | from $169 | per month, starting-dose price |
| Lowest printed rate | $139 | $90 starting dose + $49 membership on a 12-month plan |
Limitations and what to check before you enroll
Compounded tirzepatide is not FDA-approved and is not the same product as Zepbound; it is made for an individual patient by a state-licensed pharmacy. Ask Mochi Health for the all-in price at the maintenance dose, what is charged today and how often, and which pharmacy fills the prescription. A clinician decides whether any GLP-1 is right for you.
Frequently asked
How much does Mochi Health charge for tirzepatide?
As of November 20, 2026, Mochi Health charges $169 a month for compounded tirzepatide month to month, all-in, according to its own page. That is a starting-dose figure; the price rises with the dose, so ask for the maintenance-dose price in writing.
Is Mochi Health’s tirzepatide FDA-approved?
No. Compounded tirzepatide from any telehealth program, Mochi Health included, is not FDA-approved and is not the same product as Zepbound or Mounjaro. It is made for an individual patient by a state-licensed compounding pharmacy. Brand Zepbound is the FDA-approved version.
Where do these Mochi Health figures come from?
From Mochi Health’s own page (first-party read, changed, November 20, 2026), converted to an all-in month-to-month figure (medication plus any required recurring fee, before tax). The source link and read date are listed below, and the same figures are in the open dataset.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Mochi Health pricing page (read November 20, 2026)